Target Price | JPY5,682.86 |
Price | JPY5,080.00 |
Potential |
11.87%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Kobayashi Pharmaceutical 2026 .
The average Kobayashi Pharmaceutical target price is JPY5,682.86.
This is
11.87%
register free of charge
JPY6,700.00
31.89%
register free of charge
JPY5,000.00
1.57%
register free of charge
|
|
A rating was issued by 7 analysts: 2 Analysts recommend Kobayashi Pharmaceutical to buy, 5 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Kobayashi Pharmaceutical stock has an average upside potential 2026 of
11.87%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion JPY | 165.60 | 170.79 |
4.53% | 3.14% | |
EBITDA Margin | 17.93% | 15.00% |
7.33% | 24.46% | |
Net Margin | 6.08% | 7.31% |
47.10% | 20.25% |
7 Analysts have issued a sales forecast Kobayashi Pharmaceutical 2025 . The average Kobayashi Pharmaceutical sales estimate is
This results in the following potential growth metrics:
4 Kobayashi Pharmaceutical Analysts have issued a net profit forecast 2025. The average Kobayashi Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share JPY | 135.42 | 168.02 |
49.50% | 24.07% | |
P/E | 30.35 | |
EV/Sales | 1.83 |
4 Analysts have issued a Kobayashi Pharmaceutical forecast for earnings per share. The average Kobayashi Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Kobayashi Pharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.